Publications

Authors:

Cuzzolin, Laura; Oggiano, Anna Maria; Clemente, Maria Grazia; Locci, Cristian; Antonucci, Luca; Antonucci, Roberto

Title:

Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough?

Year:

2021

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

Elettronico

Referee:

No

Name of journal:

FUNDAMENTAL & CLINICAL PHARMACOLOGY

ISSN of journal:

0767-3981

N° Volume:

35

Number or Folder:

1

:

BLACKWELL PUBLISHING LTD

Page numbers:

40-52

Keyword:

biliary sludge; ceftriaxone; children; cholelithiasis; gallstones

Short description of contents:

Ceftriaxone is an antibiotic agent frequently used in paediatric hospital practice for the treatment of severe bacterial infections. The use of this agent can result in cholelithiasis and/or biliary sludge, more commonly in children than in adults. This systematic review was aimed at analysing available literature concerning ceftriaxone-associated biliary pseudolithiasis in paediatric patients, with a special emphasis on the clinical aspects. A literature analysis was performed using Medline and Embase electronic databases (articles published in English up to December 2019), with the search terms and combinations as follows:'ceftriaxone', 'cholelithiasis', 'biliary sludge' 'gallstones' 'neonates' 'children' 'clinical aspects' 'management'. Several case reports, case series and prospective/retrospective studies have documented a relationship between ceftriaxone treatment and biliary pseudolithiasis in the paediatric population, even though literature data regarding neonates and infants are scarce. Ceftriaxone-associated biliary pseudolithiasis is dose-dependent and usually asymptomatic but, sometimes, it may present with abdominal pain, nausea and emesis. Abdominal ultrasonography should be performed when this complication is suspected. Generally, ceftriaxone-associated cholelithiasis resolves over a variable period of time (days to months) after cessation of therapy. Therefore, a conservative approach to this condition is advocated, but a prolonged follow-up may be necessary. A personalized assessment of factors predisposing to ceftriaxone-associated biliary pseudolithiasis before prescribing the drug can allow to minimize the risk of developing it, with significant advantages in terms of human and economic costs.

Product ID:

118545

Handle IRIS:

11562/1032648

Last Modified:

November 15, 2022

Bibliographic citation:

Cuzzolin, Laura; Oggiano, Anna Maria; Clemente, Maria Grazia; Locci, Cristian; Antonucci, Luca; Antonucci, Roberto, Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough? «FUNDAMENTAL & CLINICAL PHARMACOLOGY» , vol. 35 , n. 1 , 2021 , pp. 40-52

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo